Research ExplorerPublicationsAnticoagulation for Percutaneous Ventricular Assist Device-S...

Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock: JACC Review Topic of the Week

Standard

Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock: JACC Review Topic of the Week. / Vandenbriele, Christophe; Arachchillage, Deepa J; Frederiks, Pascal; Giustino, Gennaro; Gorog, Diana A; Gramegna, Mario; Janssens, Stefan; Meyns, Bart; Polzin, Amin; Scandroglio, Mara; Schrage, Benedikt; Stone, Gregg W; Tavazzi, Guido; Vanassche, Thomas; Vranckx, Pascal; Westermann, Dirk; Price, Susanna; Chieffo, Alaide.

In: J AM COLL CARDIOL, Vol. 79, No. 19, 17.05.2022, p. 1949-1962.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Vandenbriele, C, Arachchillage, DJ, Frederiks, P, Giustino, G, Gorog, DA, Gramegna, M, Janssens, S, Meyns, B, Polzin, A, Scandroglio, M, Schrage, B, Stone, GW, Tavazzi, G, Vanassche, T, Vranckx, P, Westermann, D, Price, S & Chieffo, A 2022, 'Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock: JACC Review Topic of the Week', J AM COLL CARDIOL, vol. 79, no. 19, pp. 1949-1962. https://doi.org/10.1016/j.jacc.2022.02.052

APA

Vandenbriele, C., Arachchillage, D. J., Frederiks, P., Giustino, G., Gorog, D. A., Gramegna, M., Janssens, S., Meyns, B., Polzin, A., Scandroglio, M., Schrage, B., Stone, G. W., Tavazzi, G., Vanassche, T., Vranckx, P., Westermann, D., Price, S., & Chieffo, A. (2022). Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock: JACC Review Topic of the Week. J AM COLL CARDIOL, 79(19), 1949-1962. https://doi.org/10.1016/j.jacc.2022.02.052

Vancouver

Vandenbriele C, Arachchillage DJ, Frederiks P, Giustino G, Gorog DA, Gramegna M et al. Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock: JACC Review Topic of the Week. J AM COLL CARDIOL. 2022 May 17;79(19):1949-1962. https://doi.org/10.1016/j.jacc.2022.02.052

Bibtex

@article{3d2a9b56ee734dd18defaf10f6144264,
title = "Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock: JACC Review Topic of the Week",
abstract = "Interest in the use of mechanical circulatory support for patients presenting with cardiogenic shock is growing rapidly. The Impella (Abiomed Inc), a microaxial, continuous-flow, short-term, ventricular assist device (VAD), requires meticulous postimplantation management. Because systemic anticoagulation is needed to prevent pump thrombosis, patients are exposed to increased bleeding risk, further aggravated by sepsis, thrombocytopenia, and high shear stress-induced acquired von Willebrand syndrome. The precarious balance between bleeding and thrombosis in percutaneous VAD-supported cardiogenic shock patients is often the main reason that patient outcomes are jeopardized, and there is a lack of data addressing optimal anticoagulation management strategies during percutaneous VAD support. Here, we present a parallel anti-Factor Xa/activated partial thromboplastin time-guided anticoagulation algorithm and discuss pitfalls of heparin monitoring in critically ill patients. This review will guide physicians toward a more standardized (anti)coagulation approach to tackle device-related morbidity and mortality in this critically ill patient group.",
keywords = "Anticoagulants/therapeutic use, Critical Illness, Heart-Assist Devices/adverse effects, Hemorrhage/chemically induced, Humans, Retrospective Studies, Shock, Cardiogenic/etiology, Thrombosis/complications, Treatment Outcome",
author = "Christophe Vandenbriele and Arachchillage, {Deepa J} and Pascal Frederiks and Gennaro Giustino and Gorog, {Diana A} and Mario Gramegna and Stefan Janssens and Bart Meyns and Amin Polzin and Mara Scandroglio and Benedikt Schrage and Stone, {Gregg W} and Guido Tavazzi and Thomas Vanassche and Pascal Vranckx and Dirk Westermann and Susanna Price and Alaide Chieffo",
note = "Copyright {\textcopyright} 2022 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2022",
month = may,
day = "17",
doi = "10.1016/j.jacc.2022.02.052",
language = "English",
volume = "79",
pages = "1949--1962",
journal = "J AM COLL CARDIOL",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "19",

}

RIS

TY - JOUR

T1 - Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock: JACC Review Topic of the Week

AU - Vandenbriele, Christophe

AU - Arachchillage, Deepa J

AU - Frederiks, Pascal

AU - Giustino, Gennaro

AU - Gorog, Diana A

AU - Gramegna, Mario

AU - Janssens, Stefan

AU - Meyns, Bart

AU - Polzin, Amin

AU - Scandroglio, Mara

AU - Schrage, Benedikt

AU - Stone, Gregg W

AU - Tavazzi, Guido

AU - Vanassche, Thomas

AU - Vranckx, Pascal

AU - Westermann, Dirk

AU - Price, Susanna

AU - Chieffo, Alaide

N1 - Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2022/5/17

Y1 - 2022/5/17

N2 - Interest in the use of mechanical circulatory support for patients presenting with cardiogenic shock is growing rapidly. The Impella (Abiomed Inc), a microaxial, continuous-flow, short-term, ventricular assist device (VAD), requires meticulous postimplantation management. Because systemic anticoagulation is needed to prevent pump thrombosis, patients are exposed to increased bleeding risk, further aggravated by sepsis, thrombocytopenia, and high shear stress-induced acquired von Willebrand syndrome. The precarious balance between bleeding and thrombosis in percutaneous VAD-supported cardiogenic shock patients is often the main reason that patient outcomes are jeopardized, and there is a lack of data addressing optimal anticoagulation management strategies during percutaneous VAD support. Here, we present a parallel anti-Factor Xa/activated partial thromboplastin time-guided anticoagulation algorithm and discuss pitfalls of heparin monitoring in critically ill patients. This review will guide physicians toward a more standardized (anti)coagulation approach to tackle device-related morbidity and mortality in this critically ill patient group.

AB - Interest in the use of mechanical circulatory support for patients presenting with cardiogenic shock is growing rapidly. The Impella (Abiomed Inc), a microaxial, continuous-flow, short-term, ventricular assist device (VAD), requires meticulous postimplantation management. Because systemic anticoagulation is needed to prevent pump thrombosis, patients are exposed to increased bleeding risk, further aggravated by sepsis, thrombocytopenia, and high shear stress-induced acquired von Willebrand syndrome. The precarious balance between bleeding and thrombosis in percutaneous VAD-supported cardiogenic shock patients is often the main reason that patient outcomes are jeopardized, and there is a lack of data addressing optimal anticoagulation management strategies during percutaneous VAD support. Here, we present a parallel anti-Factor Xa/activated partial thromboplastin time-guided anticoagulation algorithm and discuss pitfalls of heparin monitoring in critically ill patients. This review will guide physicians toward a more standardized (anti)coagulation approach to tackle device-related morbidity and mortality in this critically ill patient group.

KW - Anticoagulants/therapeutic use

KW - Critical Illness

KW - Heart-Assist Devices/adverse effects

KW - Hemorrhage/chemically induced

KW - Humans

KW - Retrospective Studies

KW - Shock, Cardiogenic/etiology

KW - Thrombosis/complications

KW - Treatment Outcome

U2 - 10.1016/j.jacc.2022.02.052

DO - 10.1016/j.jacc.2022.02.052

M3 - SCORING: Review article

C2 - 35550692

VL - 79

SP - 1949

EP - 1962

JO - J AM COLL CARDIOL

JF - J AM COLL CARDIOL

SN - 0735-1097

IS - 19

ER -